Akers Biosciences Announces $2.5M Order to Supply PIFA Heparin/PF4 Products to China
March 02 2016 - 7:00AM
Marketwired
Akers Biosciences Announces $2.5M Order to Supply PIFA
Heparin/PF4 Products to China
THOROFARE, NJ-(Marketwired - Mar 2, 2016) - Akers Biosciences,
Inc. (NASDAQ: AKER) (AIM: AKR.L), ("Akers Bio" or the "Company"), a
developer of health information technologies, announces the receipt
of an order valued at approximately US$2,500,000 from NovoTek
Therapeutics Inc. ("NovoTek") to supply PIFA Heparin PF4/Rapid
Assay products in Mainland China ("China"). The order will be
fulfilled in tranches throughout 2016, with initial sales
anticipated prior to the end of the first quarter.
The China Food and Drug Administration ("China FDA") recently
approved the Company's rapid tests for allergic reactions
associated with the widely used blood-thinner, heparin, for medical
use throughout China. NovoTek, a Beijingbased pharmaceutical and
medical device company, holds the exclusive sales and marketing
rights for the Company's PIFA Heparin/PF4 Rapid Assay products in
China.
The Company's PIFA Heparin/PF4 Rapid Assay and PIFA PLUSS PF4
version (which tests whole blood) are the first and only tests of
any kind for PF4 antibodies (associated with the condition known as
heparin-induced thrombocytopenia ("HIT")) to be available in
China.
PIFA Heparin/PF4 Rapid Assay and PIFA PLUSS PF4 remain the only
US FDA-cleared rapid manual assays that quickly determine if a
patient being treated with the blood thinner heparin may be
developing HIT. This clinical syndrome reverses the heparin's
intended therapeutic effect and transforms it into a clotting
agent. Patients suffering HIT are at risk of developing limb- and
life-threatening complications, so the timely test result provided
by the Company's Heparin/PF4 devices is paramount to effective,
clinical decision making.
"The China FDA's approval of our test paves the way for Akers
Bio and NovoTek to establish the PIFA Heparin/PF4 Rapid Assay
devices as the gold standard for HIT testing throughout China,"
said Raymond F. Akers, Jr. PhD, Co-founder and Executive
Chairman.
"Our partner, NovoTek, is developing a complete solution to
manage HIT in the Chinese healthcare system by having the exclusive
licenses both for our test as well as for a treatment for those
patients who have been diagnosed with HIT."
"We look forward to fulfilling this order and to working with
NovoTek to build what we believe will be an increasing flow of
business for the Company over the coming years," added Dr.
Akers.
About Akers Biosciences, Inc.
Akers Biosciences develops, manufactures, and supplies rapid
screening and testing products designed to deliver quicker and more
cost-effective healthcare information to healthcare providers and
consumers. The Company has advanced the science of diagnostics
while responding to major shifts in healthcare through the
development of several proprietary platform technologies. The
Company's state-of-the-art rapid diagnostic assays can be performed
virtually anywhere in minutes when time is of the essence. The
Company has aligned with major healthcare companies and high volume
medical product distributors to maximize product offerings, and to
be a major worldwide competitor in diagnostics.
Additional information on the Company and its products can be
found at www.akersbio.com. Follow us on Twitter @AkersBio.
Cautionary Statement Regarding Forward Looking Statements
Statements contained herein that are not based upon current or
historical fact are forward-looking in nature and constitute
forward-looking statements within the meaning of Section 27A of the
Securities Act of 1933 and Section 21E of the Securities Exchange
Act of 1934. Such forward-looking statements reflect the Company's
expectations about its future operating results, performance and
opportunities that involve substantial risks and uncertainties.
These statements include but are not limited to statements
regarding the intended terms of the offering, closing of the
offering and use of any proceeds from the offering. When used
herein, the words "anticipate," "believe," "estimate," "upcoming,"
"plan," "target", "intend" and "expect" and similar expressions, as
they relate to Akers Biosciences, Inc., its subsidiaries, or its
management, are intended to identify such forward-looking
statements. These forward-looking statements are based on
information currently available to the Company and are subject to a
number of risks, uncertainties, and other factors that could cause
the Company's actual results, performance, prospects, and
opportunities to differ materially from those expressed in, or
implied by, these forward-looking statements.
Contact Information
For more information: Akers Biosciences, Inc. Raymond F. Akers,
Jr. PhD Executive Chairman of the Board Tel. +1 856 848 8698
Taglich Brothers, Inc. (Investor Relations) Chris Schreiber Tel. +1
917 445 6207 Email: cs@taglichbrothers.com finnCap (UK Nominated
Adviser and Broker) Adrian Hargrave / Scott Mathieson (Corporate
Finance) Steve Norcross (Broking) Tel. +44 (0)20 7220 0500 Vigo
Communications (Public Relations) Ben Simons / Fiona Henson Tel.
+44 (0)20 7016 9570 Email: akers@vigocomms.com
Akers Biosciences (NASDAQ:AKER)
Historical Stock Chart
From Jun 2024 to Jul 2024
Akers Biosciences (NASDAQ:AKER)
Historical Stock Chart
From Jul 2023 to Jul 2024